

September 29, 2011

ONO PHARMACEUTICAL CO., LTD.

President and Representative Director: Gyo Sagara,
Code No.:4528 at the 1st section of Tokyo / Osaka Stock Exchange
INQUIRIES: Kinya Morimoto, Executive Officer, Director, Corporate Communications

**Additional Indication Application Filed for a Drug for the Prevention of
Chemotherapy-Induced Nausea and Vomiting “EMEND[®] Capsule” for
Pediatric Patients Aged 12 and older**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced today that an additional application for pediatric patients aged 12 and older for an antiemetic drug, “EMEND[®] Capsule” was submitted today.

The drug was originally discovered by Merck Sharp & Dohme Corp., (MSD, known as Merck inside the United States and Canada), and granted an exclusive license to Ono for development and commercialization in Japan in November 2004.

Ono launched “EMEND[®] Capsule” (INN: aprepitant), a drug for the prevention of chemotherapy-induced nausea and vomiting, in December 2009. Since then EMEND[®] Capsule has been widely used in adult patients who suffer from chemotherapy-induced nausea and vomiting. However, because EMEND[®] Capsule is not currently indicated for pediatric patients, an additional indication of the drug for pediatric patients is strongly desired in clinical practice, and “the Japanese Society of Pediatric Hematology” and “Japanese Society of Pediatric Oncology” have submitted requests to Ministry of Health, Labor and Welfare.

Ono had therefore developed EMEND[®] Capsule for an additional indication for nausea, vomiting resulting from the administration of antineoplastic agents for pediatric patients actively in order to meet such clinical needs.

We shall continue our utmost best in order to obtain an early approval of additional indication for pediatric patients aged 12 and older as well as review the development for pediatric patients aged less than 12 years.